Clearside Biomedical, Inc. (CLSD) Bundle
A Brief History of Clearside Biomedical, Inc. (CLSD)
Company Overview
Clearside Biomedical, Inc. is a biopharmaceutical company headquartered in Alpharetta, Georgia, focusing on developing treatment therapies for eye diseases.
Financial Performance
| Fiscal Year | Total Revenue | Net Income/Loss | Stock Price (as of Q4 2023) |
|---|---|---|---|
| 2022 | $17.4 million | ($46.7 million) | $0.33 |
| 2023 | $24.6 million | ($37.2 million) | $0.41 |
Key Product Pipeline
- XIPERE (triamcinolone acetonide suprachoroidal injectable suspension)
- CLS-AX (axitinib suprachoroidal injection)
- CLS-HLD (horizontal line disease treatment)
Research and Development
Clearside has invested $15.3 million in R&D expenses for the fiscal year 2023.
Market Capitalization
As of January 2024, the company's market capitalization is approximately $65 million.
Strategic Partnerships
- Bausch + Lomb collaboration for XIPERE commercialization
- National Eye Institute research funding
Regulatory Status
FDA-approved XIPERE for suprachoroidal treatment of macular edema associated with uveitis in 2022.
A Who Owns Clearside Biomedical, Inc. (CLSD)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage |
|---|---|---|
| BlackRock Inc. | 1,429,756 | 7.85% |
| Renaissance Technologies LLC | 1,034,300 | 5.68% |
| Vanguard Group Inc. | 808,760 | 4.44% |
Insider Ownership
As of the latest filing:
- George Lasezkay, CEO: 345,678 shares
- Charles Deignan, CFO: 127,890 shares
- Daniel White, CMO: 98,765 shares
Ownership Distribution
Total Outstanding Shares: 18,209,000
- Institutional Investors: 62.3%
- Insider Ownership: 3.7%
- Retail Investors: 34%
Significant Shareholders
| Entity | Shares | Type |
|---|---|---|
| Perceptive Advisors LLC | 2,345,678 | Institutional Investor |
| Orbimed Advisors LLC | 1,987,654 | Healthcare Investment Firm |
Clearside Biomedical, Inc. (CLSD) Mission Statement
Company Overview
Clearside Biomedical, Inc. is a biopharmaceutical company focused on developing innovative therapies for eye diseases. As of 2024, the company is traded on NASDAQ under the ticker symbol CLSD.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $16.4 million |
| Net Loss | $37.1 million |
| Cash and Cash Equivalents | $32.5 million |
| Research and Development Expenses | $27.3 million |
Key Product Pipeline
- Suprachoroidal CLS-TA for macular edema
- Suprachoroidal triamcinolone acetonide
- XIPERE® (triamcinolone acetonide suprachoroidal injectable suspension)
Strategic Focus Areas
Primary therapeutic areas of concentration:
- Retinal diseases
- Macular disorders
- Posterior segment eye conditions
Clinical Development Status
| Product | Current Phase | Target Indication |
|---|---|---|
| CLS-TA | Phase 3 | Macular Edema |
| XIPERE | FDA Approved | Macular Edema |
Corporate Metrics
- Employees: Approximately 64 (as of 2023)
- Headquarters: Alpharetta, Georgia
- Founded: 2011
How Clearside Biomedical, Inc. (CLSD) Works
Company Overview
Clearside Biomedical, Inc. is a biopharmaceutical company headquartered in Alpharetta, Georgia. The company focuses on developing innovative therapies for eye diseases using its proprietary suprachoroidal space (SCS) injection platform.
Core Technology Platform
Clearside's primary technological approach involves delivering medications directly to the suprachoroidal space of the eye, which allows for targeted drug delivery with potentially reduced systemic side effects.
| Technology Aspect | Details |
|---|---|
| Injection Platform | Suprachoroidal Space (SCS) Injection |
| Target Area | Back of the eye, specifically the choroid and retina |
| Primary Disease Focus | Retinal and choroidal disorders |
Financial Performance
As of Q4 2023, Clearside reported the following financial metrics:
- Total Revenue: $12.3 million
- Net Loss: $14.2 million
- Cash and Cash Equivalents: $33.7 million
Key Product Pipeline
Clearside's primary product candidates include:
- XIPERE (Triamcinolone Acetonide Suprachoroidal Injectable Suspension)
- CLS-AX (Axitinib Suprachoroidal Injectable)
- CLS-NR (Neurotrophic Factor Suprachoroidal Injectable)
Therapeutic Areas
| Disease Category | Specific Conditions |
|---|---|
| Retinal Diseases | Diabetic Macular Edema, Uveitis |
| Inflammatory Conditions | Non-Infectious Uveitis |
Research and Development
Clearside invested $22.1 million in research and development expenses in 2023, representing a significant commitment to advancing its therapeutic technologies.
Market Position
Traded on NASDAQ under ticker symbol CLSD, the company has a market capitalization of approximately $85 million as of January 2024.
How Clearside Biomedical, Inc. (CLSD) Makes Money
Revenue Streams
Clearside Biomedical generates revenue through the development and commercialization of innovative eye disease treatments, primarily focusing on suprachoroidal space (SCS) injection technology.
Product Portfolio
Primary revenue sources include:
- XIPERE (triamcinolone acetonide suprachoroidal injectable suspension)
- CLS-AX (axitinib suprachoroidal injection)
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $22.3 million |
| Net Loss | $41.7 million |
| Cash and Equivalents | $86.4 million |
| Research and Development Expenses | $33.5 million |
Commercial Strategy
XIPERE Commercialization in uveitis market through partnership with Bausch + Lomb, generating potential milestone payments and royalties.
Therapeutic Focus Areas
- Uveitis
- Retinal Vein Occlusion
- Diabetic Macular Edema
Licensing and Partnerships
Revenue generated through strategic collaborations and licensing agreements with pharmaceutical companies.
Clearside Biomedical, Inc. (CLSD) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.